77
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Benzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein–ligand crystallography

      research-article
      a , a , b , a , b , a , a , b , a , a , b , * , a , *
      Bioorganic & Medicinal Chemistry
      Elsevier Science
      ADP, adenosine diphosphate, ATM, ataxia telangiectasia mutated, ATP, adenosine triphosphate, CHK2, checkpoint kinase 2, GOLD, genetic optimisation for ligand docking, GST, glutathione S-transferase, KD, kinase domain, MOE, molecular operating environment, PARP, poly ADP-ribose polymerase, PDB, protein data bank, PLIF, protein ligand interaction fingerprints, SAR, structure activity relationship, SIFt, structural interaction fingerprints, Kinase, CHK2, Flexible docking, Crystallography, Inhibitor

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Graphical abstract

          Unconstrained rigid docking, flexible side chain docking and protein crystal structure determinations reveal a water-mediated hinge binding mode for a series of benzimidazole ligands of the protein kinase CHK2. This binding mode is different from those previously postulated in the literature and may provide a useful approach to selective small molecule inhibitor design.

          Abstract

          Two closely related binding modes have previously been proposed for the ATP-competitive benzimidazole class of checkpoint kinase 2 (CHK2) inhibitors; however, neither binding mode is entirely consistent with the reported SAR. Unconstrained rigid docking of benzimidazole ligands into representative CHK2 protein crystal structures reveals an alternative binding mode involving a water-mediated interaction with the hinge region; docking which incorporates protein side chain flexibility for selected residues in the ATP binding site resulted in a refinement of the water-mediated hinge binding mode that is consistent with observed SAR. The flexible docking results are in good agreement with the crystal structures of four exemplar benzimidazole ligands bound to CHK2 which unambiguously confirmed the binding mode of these inhibitors, including the water-mediated interaction with the hinge region, and which is significantly different from binding modes previously postulated in the literature.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Improved protein-ligand docking using GOLD.

          The Chemscore function was implemented as a scoring function for the protein-ligand docking program GOLD, and its performance compared to the original Goldscore function and two consensus docking protocols, "Goldscore-CS" and "Chemscore-GS," in terms of docking accuracy, prediction of binding affinities, and speed. In the "Goldscore-CS" protocol, dockings produced with the Goldscore function are scored and ranked with the Chemscore function; in the "Chemscore-GS" protocol, dockings produced with the Chemscore function are scored and ranked with the Goldscore function. Comparisons were made for a "clean" set of 224 protein-ligand complexes, and for two subsets of this set, one for which the ligands are "drug-like," the other for which they are "fragment-like." For "drug-like" and "fragment-like" ligands, the docking accuracies obtained with Chemscore and Goldscore functions are similar. For larger ligands, Goldscore gives superior results. Docking with the Chemscore function is up to three times faster than docking with the Goldscore function. Both combined docking protocols give significant improvements in docking accuracy over the use of the Goldscore or Chemscore function alone. "Goldscore-CS" gives success rates of up to 81% (top-ranked GOLD solution within 2.0 A of the experimental binding mode) for the "clean list," but at the cost of long search times. For most virtual screening applications, "Chemscore-GS" seems optimal; search settings that give docking speeds of around 0.25-1.3 min/compound have success rates of about 78% for "drug-like" compounds and 85% for "fragment-like" compounds. In terms of producing binding energy estimates, the Goldscore function appears to perform better than the Chemscore function and the two consensus protocols, particularly for faster search settings. Even at docking speeds of around 1-2 min/compound, the Goldscore function predicts binding energies with a standard deviation of approximately 10.5 kJ/mol. Copyright 2003 Wiley-Liss, Inc.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Design, synthesis and selection of DNA-encoded small-molecule libraries.

            Biochemical combinatorial techniques such as phage display, RNA display and oligonucleotide aptamers have proven to be reliable methods for generation of ligands to protein targets. Adapting these techniques to small synthetic molecules has been a long-sought goal. We report the synthesis and interrogation of an 800-million-member DNA-encoded library in which small molecules are covalently attached to an encoding oligonucleotide. The library was assembled by a combination of chemical and enzymatic synthesis, and interrogated by affinity selection. We describe methods for the selection and deconvolution of the chemical display library, and the discovery of inhibitors for two enzymes: Aurora A kinase and p38 MAP kinase.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

              Insights from cell cycle research have led to the hypothesis that tumors may be selectively sensitized to DNA-damaging agents resulting in improved antitumor activity and a wider therapeutic margin. The theory relies on the observation that the majority of tumors are deficient in the G1-DNA damage checkpoint pathway resulting in reliance on S and G2 checkpoints for DNA repair and cell survival. The S and G2 checkpoints are regulated by checkpoint kinase 1, a serine/threonine kinase that is activated in response to DNA damage; thus, inhibition of checkpoint kinase 1 signaling impairs DNA repair and increases tumor cell death. Normal tissues, however, have a functioning G1 checkpoint signaling pathway allowing for DNA repair and cell survival. Here, we describe the preclinical profile of AZD7762, a potent ATP-competitive checkpoint kinase inhibitor in clinical trials. AZD7762 has been profiled extensively in vitro and in vivo in combination with DNA-damaging agents and has been shown to potentiate response in several different settings where inhibition of checkpoint kinase results in the abrogation of DNA damage-induced cell cycle arrest. Dose-dependent potentiation of antitumor activity, when AZD7762 is administered in combination with DNA-damaging agents, has been observed in multiple xenograft models with several DNA-damaging agents, further supporting the potential of checkpoint kinase inhibitors to enhance the efficacy of both conventional chemotherapy and radiotherapy and increase patient response rates in a variety of settings.
                Bookmark

                Author and article information

                Journal
                Bioorg Med Chem
                Bioorg. Med. Chem
                Bioorganic & Medicinal Chemistry
                Elsevier Science
                0968-0896
                1464-3391
                15 November 2012
                15 November 2012
                : 20
                : 22
                : 6630-6639
                Affiliations
                [a ]Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, UK
                [b ]Division of Structural Biology, Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London SW3 6JB, UK
                Author notes
                [* ]Corresponding authors. Tel.: +44 208 722 5142 (R.L.M.v.M.); tel.: +44 208 722 4051 (J.B.). Rob.vanMontfort@ 123456icr.ac.uk Julian.blagg@ 123456icr.ac.uk
                Article
                S0968-0896(12)00736-5
                10.1016/j.bmc.2012.09.024
                3778940
                23058106
                f4c239b5-e177-46b8-be60-4db70459f3fa
                © 2012 Elsevier Ltd.

                This document may be redistributed and reused, subject to certain conditions.

                History
                : 22 June 2012
                : 7 September 2012
                : 13 September 2012
                Categories
                Article

                Pharmaceutical chemistry
                parp, poly adp-ribose polymerase,chk2, checkpoint kinase 2,atm, ataxia telangiectasia mutated,kinase,crystallography,kd, kinase domain,pdb, protein data bank,plif, protein ligand interaction fingerprints,gold, genetic optimisation for ligand docking,sift, structural interaction fingerprints,moe, molecular operating environment,chk2,inhibitor,gst, glutathione s-transferase,adp, adenosine diphosphate,sar, structure activity relationship,flexible docking,atp, adenosine triphosphate

                Comments

                Comment on this article